The effect of olanzapine on cognitive functions of patients with schizophrenia;Olanzapinin şizofreni hastalarinda bilişsel i̇slevlere olan etkisi

Klinik Psikofarmakoloji Bulteni

Volumn 16, Issue 4, 2006, Pages 213-222

  Inanli, Ikbal Çivi ^a   Eren, Ibrahim ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Cognitive functions; Olanzapine; Schizophrenia; Trail making test; WCST

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; MALE; MEDICAL ERROR; NEUROPSYCHOLOGICAL TEST; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT DURATION;

EID: 33845944945     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Ceylan ME, Çetin M (ed). Araştirma ve klinik uygulamada Biyolojik Psikiyatri- Şizofreni 3. Baski; 2005
2. Riley EM, McGovern D, Mockler D, Doku VC, OCeallaigh S, Fannon DG, Tennakoon L, Santamaria M, Soni W, Morris RG, Sharma T. Neuropsychological functioning in first-episode psychosis evidence of specific deficits. Schizophr Res 2000; 43:47-55
3. Hughes C, Kumari V, Soni W, Das M, Binneman B, Drozd S, O'Neil S, Mathew V, Sharma T. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res 2003; 59:137-146
4. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321-330
5. Mortimer AM. Cognitive function in schizophrenia- do neuroleptics make a difference? Pharmacol Biochem Behav 1997; 56: 789-795
6. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990;16: 477-499
7. Nestor PG, Faux SF, McCarley RW, Sands SF, Horvath TB, Peterson A. Neuroleptics improve sustained attention in schizophrenia: a study using signal detection theory. Neuropsychopharmacology 1991; 4: 145-149
8. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull 1992; 28: 353-366
9. Bilder RM, Lipschultz-Broch L, Reiter G, Mayerhoff D, Loebel A, Degreef G, Ashtari M, Lieberman JA. Neuropsychological studies of first episode schizophrenia. Schizophr Res 1991; 4: 381-382
10. Meltzer HY, McGurk SR. The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schiz Bull 1999; 25: 233-255
11. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia insights from brain imaging studies. Eur Psychiatry 2005; 20:15-27
12. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefsonn GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psych. 2000; 5: 249-258
13. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10:799-812
14. Soykan Ç. Institutional differences and case typicality as diagnosis system severity, prognosis and treatment. Master Tezi. Orta Doǧu Teknik Üniversitesi 1990
15. Kay SR, Fiszbein A, Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 1987; 13: 261-276
16. Kostakoǧlu AE, Batur S, Tiryaki A. Pozitif ve Negatif Sendrom Ölçǧinin (PANSS) Türkçe Uyarlamasinin Geçerlik ve Güvenilirliǧ;i. Türk Psikoloji Dergisi 1999; 14:23-32
17. Guy W. ECDEU Assessment manual for psychopharmacology, CDHEW 1976; No: 76-338, US Department of Health, Education and Welfare, Rockville, MD, S. 217-222
18. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenia. Schizophr Res 1994; 11: 239-244
19. Aydemir Ö, Danaci Esen A, Deveci A, İçelli İ. Calgary Şizofrenide Depresyon Ölçeǧi'nin Türkçe versiyonunun güvenilirliǧi ve geçerliliǧi. Nöropsikiyatri Arşivi 2000; 37:82-86
20. Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7: 233
21. Grant DA, Berg EA. A behavioural analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card sorting problem. J Exp Psychology 1948;38: 404-411
22. Karakaş S, Irak M, Kurt M, Erzengin ÖU. Wisconsin Kart Eşleme Testi ve Stroop Testi TBAG Formu: Ölçülen özellikler açisindan karşilaştirmali analiz. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1999; 7: 179-192
23. Reitan RM. Trail Making Test. Manual for Administration and Scoring. Reitan Neuropsychological Laboratory, 1992;South Tucson, AZ
24. Zangwill OL. Clinical tests of memory impairment. Proc Royal Soc Med 1943; 36:576-580
25. Cantez E, Akça Ş, Akkapulu F, Bekçi B, Canli P, Çakar A, Yildirim S. BİLNOT Bataryasi Testlerinden İşaretleme Testi ve Sayi Dizisi Öǧrenme Testi'nin test-tekrar test güvenirlik çalişmasi. IX. Ulusal Psikoloji Kongresi, 1996; İstanbul
26. Purdon SE, Labelle A, Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr Res 2001; 48:57-67
27. Stratta P, Donda P, Rossi A, Rossi A. Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study. Hum Psychopharmacol Clin Exp 2005; 20: 401-408
28. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25:201-222
29. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158:176-184
30. McGurk SR, Lee MA, Jayathilake K, Meltzer HY. Cognitive effects of olanzapine treatment in schizophrenia. Med Gen Med 2004; 6:27
31. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159:1018-1028
32. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia:a longitudinal study. Schizophr Res 2001; 48:17-28
33. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A: HGGN Study Group. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006; 81:1-15
34. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161:985-995
35. Sharma T, Hughes C, Soni W, Kumari V. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology 2003;16: 398-403
36. Andreasen NC, Rezai K, Alliger R, Swayze VW II, şaum M, Kirchner P, Cohen G, O'Leary DS. Hypofrontality in neuroleptic-naïve patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992; 49:943-958
37. Chengappa KNR, Pollock BG, Parepally H, Levine J, Kirshner MA, Brar JS. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 2000; 20:311-316
38. Weiser M, Shneider-Beeri M, Nakash N, Brill N, Bawnik O, Reiss S, Hocherman S, Davidson M. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS? Schizophr Res 2000; 46:81-89
39. Okubo Y, Shuhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385, 634-636
40. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999; 45: 1-16
41. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160 (Suppl 17): S43-S53
42. Hagger C, Buckley P, Kenny JT, Fiedman L, Ubogy D, Meltzer HY. Improvement in cognitive function and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702-712
43. Zahn, TP, Pickar D, Haier RJ. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res 1994; 13, 133-144
44. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, Csernansky JG. The effect of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic patients. Neuropsychopharmacology 1996; 15: 361-369
45. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996; 41 (Suppl 2), S35-S40
46. Galletly CA, Clark CR, McFarlane AC, Weber DL. Relationships between changes in symptom ratings, neuropsychological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res 1997; 72, 161-166
47. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997; 154: 799-804
48. Scarr E, Copolov DL, Dean B. A proposed pathological model in the hippocampus of subjects with schizophrenia. Clin Exp Pharmacol Physiol 2001; 28:70-73
49. Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry 1997; 42: 255-264
50. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 1997; 17:2785-2795
51. Sapolsky RM. The physiological relevance of glucocorticoid endangerment of the hippocampus. Ann NY Acad Sci USA 1994; 746:294-304
52. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251:238-246